BMT- BIO MARKETING Inc. of Zichron Yaacov at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine

BMT- BIO MARKETING Inc.

P.O. Box 420, 23091096 Zichron Yaacov
14, Hailan st, 23091096 Zichron Yaacov
Israel
Telephone +972 4 63961160
Fax +972 4 6396995
nili@bmt.co.il

This company is co-exhibitor of
Israel Export & International Cooperation Institute

Hall map

MEDICA 2019 hall map (Hall 16): stand M25

Fairground map

MEDICA 2019 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.05  Infectious immunology testing
  • 03.05.03  Other infectious immunology testing

Our products

Product category: Other infectious immunology testing

Gonorrhea Rapid Test Cassette

Specimen: Swab | Format: Cassette | Kit size: 20 T

More Less

Product category: Other infectious immunology testing

HAV IgM Rapid Test Cassette

Specimen: S / P | Format: Cassette | Kit size: 25 T

More Less

Product category: Other infectious immunology testing

HAV IgG Rapid Test Cassette

Specimen: S / P | Format: Cassette | Kit size: 25 T

More Less

Product category: Other infectious immunology testing

HAV IgG/IgM Rapid Test Cassette

Specimen: S / P | Format: Cassette | Kit size: 25 T

More Less

Product category: Other infectious immunology testing

H. pylori Antibody Rapid Test Cassette

Specimen: S / P | Format: Cassette | Kit size: 40 T

More Less

Product category: Other infectious immunology testing

Rotavirus Rapid Test Cassette

Specimen: Feces | Format: Cassette | Kit size: 25 T

More Less

About us

Company details

Founded in 2004, BMT Diagnostics is an Israeli company with a business focus on providing rapid diagnostic solutions to the point-of-care (POC) and for self-testing.

BMT Diagnostics was the first company to introduce rapid tests for Strep A diagnosis to Israeli pharmacies, allowing patients to purchase these tests over-the-counter (OTC) prior to visiting their primary care physician. This strategy aimed at improving the process of patient`s screening at the physician`s office, thereby reducing antibiotics abuse by preventing their administration to patients tested negative for Strep A. An additional goal for this strategy was to shift Strep A screening from centralized labs to point-of-care, improving HMO service at times the centralized lab was inoperative (e.g., weekends) or overloaded.

In recent years, BMT has captured an additional market segment by selling its tests directly to leading HMOs who distribute them internally in their clinics. Of the estimated two million Strep A tests performed annually in Israel, around 500,000 are RDT, thereby validating our business model that is based on patients assuming responsibility for their own health first, followed by ENT and family physicians adoption and acceptance of Strep A RDT as a first-line diagnostic standard.

More Less